MIF-1 (Melanostatin)
Tripeptide D2 receptor modulator with old but real human Parkinson's data.
For research purposes only. These products are not intended to diagnose, treat, cure, or prevent any disease. By purchasing, you confirm these products will be used for legitimate research purposes.
About MIF-1 (Melanostatin)
MIF-1 is Pro-Leu-Gly-NH2, also called melanostatin — a hypothalamic tripeptide originally characterised for its role in regulating melanocyte-stimulating hormone release. Its more interesting pharmacology is dopaminergic: it acts as a positive allosteric modulator at the dopamine D2 receptor, with selectivity for the postsynaptic D2L subtype and no effect on D1 or D3 binding. That mechanism — modulating a receptor's response to dopamine rather than acting as an agonist itself — is unusual among research peptides. It also has human clinical history, which sets it apart from the rest of this batch. Clinical studies reported that MIF-1 alone or combined with L-dopa had a favourable effect on tremor, rigidity, and akinesia in Parkinson's patients, and it has been investigated for depression. Those studies are old and small by modern standards, so the evidence should be read as suggestive rather than established, but it is genuine human data. Being a tripeptide, it is small enough that central penetration is more plausible than for the larger peptides here.
Key Benefits
- Positive allosteric modulator at the D2L receptor, selective over D1 and D3
- Older clinical reports of benefit on tremor, rigidity and akinesia in Parkinson's
- Small tripeptide — central penetration more plausible than for larger peptides
- Investigated for depression as well as Parkinson's
Set a goal (top of the page) to see how MIF-1 (Melanostatin) scores against it, and what the better-evidenced alternatives are.
Category Ratings
How to Take
Common Side Effects
- Poorly characterised — the human studies are old and small
- Dopaminergic modulation could theoretically affect mood or movement
- Injection site reactions
Legal & Regulatory Status
Research use only. Not FDA-approved. Human clinical studies in Parkinson's disease and depression exist but are decades old and small; the compound was never developed to approval.
Safety and regulatory details for FDA-approved compounds are drawn from the official product label via openFDA; clinical development status reflects ClinicalTrials.gov. This information is provided for research reference, is not endorsed by the FDA, and may not be complete or current.
Research & Sources
- MIF-1 picolinoyl peptidomimetics as positive allosteric modulators of D2R — describes the clinical background (PMID 31347842)
- Brain activation by peptide Pro-Leu-Gly-NH2 (MIF-1) (PMC2915805)
- Stapling amantadine to melanostatin — potent positive allosteric modulators of D2 receptors (PMC10726482)
Sources are selected for reliability (peer-reviewed literature, openFDA, ClinicalTrials.gov) but this is a research summary, not medical advice, and may not be exhaustive.
Prices at quality-checked sources · as of August 2026 (8 days ago)
- 5mg $140.34
Observed on each vendor’s public listing — see how these sources are vetted. Peptide Concierge doesn’t sell peptides and isn’t affiliated with any vendor; confirm current pricing at the source.
Builds a working set shared across the stack builder, calculator, scheduler and compare.